- Home
- MUR vs APGE Comparison
MUR vs APGE Comparison
Compare MUR & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUR | APGE |
|---|---|---|
| Founded | 1950 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.6B | 4.7B |
| IPO Year | 1994 | 2023 |
Fundamental Metrics
Financial Performance| Metric | MUR | APGE |
|---|---|---|
| Price | $39.55 | $134.10 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 13 |
| Target Price | $34.36 | ★ $109.67 |
| AVG Volume (30 Days) | ★ 1.4M | 1.2M |
| Earning Date | 05-06-2026 | 05-12-2026 |
| Dividend Yield | ★ 3.35% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.37 | N/A |
| Revenue | ★ $2,718,823,000.00 | N/A |
| Revenue This Year | $9.45 | N/A |
| Revenue Next Year | $3.94 | N/A |
| P/E Ratio | $103.22 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $21.86 | $34.34 |
| 52 Week High | $43.34 | $134.46 |
Technical Indicators
Market Signals| Indicator | MUR | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 57.80 | 79.07 |
| Support Level | $35.55 | $80.52 |
| Resistance Level | $40.63 | N/A |
| Average True Range (ATR) | 1.08 | 0.28 |
| MACD | 0.30 | -1.62 |
| Stochastic Oscillator | 69.46 | 53.08 |
Price Performance
Historical ComparisonAbout MUR Murphy Oil Corporation
Murphy Oil Corp is an oil and gas exploration and production company, with both onshore and offshore operations and properties. It operates in two geographic reportable segments the United States and Canada. It generates the majority of its revenue form the United States. The company also generates revenue from sales of oil and natural gas production activities.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a clinical-stage biotechnology company engaged in advancing optimized, novel biologics with the potential for differentiated efficacy and dosing in the inflammatory and immunology (I&I) markets, including for the treatment of atopic dermatitis (AD), asthma, eosinophilic esophagitis (EoE), chronic obstructive pulmonary disease (COPD), and other I&I indications. . Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.